Literature DB >> 22234937

Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.

Jessica C Amlin-Van Schaick1, Sungjin Kim, Christina DiFabio, Min-Hyung Lee, Karl W Broman, Karlyne M Reilly.   

Abstract

While many cancers show a sex bias, the genetic basis and molecular mechanisms underlying sex bias are not always clear. Astrocytoma and glioblastoma show male predominance in humans. We have shown previously that glial tumors forming in the Nf1-/+; Trp53-/+cis (NPcis) mouse model also show a sex bias in some genetic contexts. Using cross-species comparisons we have identified candidate male-specific modifiers of astrocytoma/glioblastoma. Linkage analysis of B6X(B6X129)-NPcis mice identifies a modifier of astrocytoma resistance specific to males, named Arlm1, on distal mouse Chr 12. Arlm1 is syntenic to human Chr 7p15, 7p21, 7q36, and 14q32 regions that are altered in human glioblastoma. A subset of these genes shows male-specific correlations to glioblastoma patient survival time and represents strong candidates for the Arlm1 modifier gene. Identification of male-specific modifier genes will lead to a better understanding of the molecular basis of male predominance in astrocytoma and glioblastoma.

Entities:  

Mesh:

Year:  2012        PMID: 22234937      PMCID: PMC3266387          DOI: 10.1093/neuonc/nor206

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  66 in total

1.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.

Authors:  Lucia A Hindorff; Praveen Sethupathy; Heather A Junkins; Erin M Ramos; Jayashri P Mehta; Francis S Collins; Teri A Manolio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

2.  Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients.

Authors:  Zeyad J El-Akawi; Fatin K Al-Hindawi; Nabil A Bashir
Journal:  Neuro Endocrinol Lett       Date:  2008-08       Impact factor: 0.765

3.  IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.

Authors:  Joseph L Wiemels; David Wilson; Chirag Patil; Joseph Patoka; Lucie McCoy; Terri Rice; Judith Schwartzbaum; Amy Heimberger; John H Sampson; Susan Chang; Michael Prados; John K Wiencke; Margaret Wrensch
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

Review 4.  MicroRNAs in Cancer.

Authors:  Ramiro Garzon; George A Calin; Carlo M Croce
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

5.  Recombination activator function of the novel RAD51- and RAD51B-binding protein, human EVL.

Authors:  Motoki Takaku; Shinichi Machida; Noriko Hosoya; Shugo Nakayama; Yoshimasa Takizawa; Isao Sakane; Takehiko Shibata; Kiyoshi Miyagawa; Hitoshi Kurumizaka
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

6.  Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner.

Authors:  Jessica C Walrath; Kristi Fox; Erika Truffer; W Gregory Alvord; Octavio A Quiñones; Karlyne M Reilly
Journal:  Mamm Genome       Date:  2009-04-04       Impact factor: 2.957

7.  Microcephalin/MCPH1 associates with the Condensin II complex to function in homologous recombination repair.

Authors:  Jamie L Wood; Yulong Liang; Kaiyi Li; Junjie Chen
Journal:  J Biol Chem       Date:  2008-08-21       Impact factor: 5.157

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study.

Authors:  Keke Zhou; Yanhong Liu; Haishi Zhang; Hongliang Liu; Weiwei Fan; Yu Zhong; Zhonghui Xu; Li Jin; Qingyi Wei; Fengping Huang; Daru Lu; Liangfu Zhou
Journal:  Int J Cancer       Date:  2009-06-15       Impact factor: 7.396

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more
  11 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

Authors:  Nicole M Warrington; Tao Sun; Jingqin Luo; Robert C McKinstry; Patricia C Parkin; Sara Ganzhorn; Debra Spoljaric; Anne C Albers; Amanda Merkelson; Douglas R Stewart; David A Stevenson; David Viskochil; Todd E Druley; Jason T Forys; Karlyne M Reilly; Michael J Fisher; Uri Tabori; Jeffrey C Allen; Joshua D Schiffman; David H Gutmann; Joshua B Rubin
Journal:  Cancer Res       Date:  2014-11-07       Impact factor: 12.701

3.  Exploring the genetic basis for clinical variation in neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Expert Rev Neurother       Date:  2016-05-30       Impact factor: 4.618

4.  Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males.

Authors:  Tao Sun; Nicole M Warrington; Jingqin Luo; Michael D Brooks; Sonika Dahiya; Steven C Snyder; Rajarshi Sengupta; Joshua B Rubin
Journal:  J Clin Invest       Date:  2014-08-01       Impact factor: 14.808

Review 5.  Pediatric gliomas as neurodevelopmental disorders.

Authors:  Suzanne J Baker; David W Ellison; David H Gutmann
Journal:  Glia       Date:  2015-12-06       Impact factor: 7.452

Review 6.  Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

7.  Intersections at the crossroads: Neurofibromatosis type 1, cAMP, sex, and glioma risk.

Authors:  Joshua B Rubin
Journal:  Mol Cell Oncol       Date:  2015-08-03

Review 8.  An integrative view on sex differences in brain tumors.

Authors:  Tao Sun; Anya Plutynski; Stacey Ward; Joshua B Rubin
Journal:  Cell Mol Life Sci       Date:  2015-05-19       Impact factor: 9.261

9.  Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.

Authors:  Alexander Pemov; Heejong Sung; Paula L Hyland; Jennifer L Sloan; Sarah L Ruppert; Andrea M Baldwin; Joseph F Boland; Sara E Bass; Hyo Jung Lee; Kristine M Jones; Xijun Zhang; James C Mullikin; Brigitte C Widemann; Alexander F Wilson; Douglas R Stewart
Journal:  PLoS Genet       Date:  2014-10-16       Impact factor: 5.917

10.  The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.

Authors:  Carlos E Prada; Robert B Hufnagel; Trent R Hummel; Anne M Lovell; Robert J Hopkin; Howard M Saal; Elizabeth K Schorry
Journal:  J Pediatr       Date:  2015-07-29       Impact factor: 6.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.